patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_773266 | REC_0003201 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.4 | 70 | female | 1 | 65 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.4 | true | MSS | 2026-03-15T05:35:57.634390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202935 | REC_0003202 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 9.7 | 70 | female | 1 | 9 | 4.2 | 2 | pembrolizumab 200 mg q3w | 19.5 | false | MSS | 2026-03-15T05:35:57.634625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730348 | REC_0003203 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.3 | 79 | female | 1 | 11 | 4.4 | 2 | alectinib 600 mg BID | 20.8 | false | MSI-H | 2026-03-15T05:35:57.634862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237487 | REC_0003204 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 8.7 | 58 | female | 0 | 44 | 6 | 8 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.635095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758240 | REC_0003205 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 15.5 | 70 | female | 2 | 12 | 6.4 | 2 | pembrolizumab 200 mg q3w | 22.6 | true | MSS | 2026-03-15T05:35:57.635325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491258 | REC_0003206 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 16.8 | 59 | female | 0 | 17 | 6.7 | 1 | pembrolizumab 200 mg q3w | 24.1 | false | MSS | 2026-03-15T05:35:57.635561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346767 | REC_0003207 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.3 | 74 | female | 2 | 12 | 5.7 | 5 | sotorasib 960 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:57.635791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477740 | REC_0003208 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 9.5 | 70 | female | 1 | 8 | 5.3 | 4 | alectinib 600 mg BID | 12.6 | true | MSS | 2026-03-15T05:35:57.636017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998292 | REC_0003209 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.2 | 71 | female | 1 | 46 | 5.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:57.636345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726020 | REC_0003210 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 16.5 | 66 | female | 0 | 7 | 5.4 | 5 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:57.636584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290877 | REC_0003211 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11.3 | 74 | female | 1 | 12 | 6.8 | 2 | alectinib 600 mg BID | 8.5 | true | MSI-H | 2026-03-15T05:35:57.636822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130134 | REC_0003212 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.3 | 66 | female | 0 | 52 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:35:57.637113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676936 | REC_0003213 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 7.3 | 66 | male | 1 | 20 | 4.5 | 0 | alectinib 600 mg BID | 38.6 | false | MSS | 2026-03-15T05:35:57.637352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919348 | REC_0003214 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.2 | 68 | female | 1 | 49 | 4.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:35:57.637579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529100 | REC_0003215 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 18.1 | 61 | male | 1 | 11 | 5.3 | 5 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:57.637820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182284 | REC_0003216 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 13.4 | 57 | female | 1 | 9 | 4.7 | 0 | osimertinib 80 mg daily | 26.3 | false | MSI-H | 2026-03-15T05:35:57.638054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296502 | REC_0003217 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.3 | 69 | male | 0 | 51 | 4.7 | 8 | pembrolizumab 200 mg q3w | 9.5 | true | MSS | 2026-03-15T05:35:57.638288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706909 | REC_0003218 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.1 | 52 | female | 0 | 7 | 5.2 | 6 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:57.638522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504560 | REC_0003219 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.5 | 71 | female | 1 | 18 | 8.2 | 5 | sotorasib 960 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:57.638756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284353 | REC_0003220 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.1 | 56 | male | 1 | 9 | 5.2 | 1 | sotorasib 960 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.638990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122978 | REC_0003221 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 12.8 | 62 | female | 0 | 18 | 3.8 | 0 | osimertinib 80 mg daily | 39.5 | true | MSS | 2026-03-15T05:35:57.639226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926245 | REC_0003222 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.5 | 50 | female | 0 | 14 | 4.3 | 5 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.639464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659209 | REC_0003223 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.6 | 62 | female | 1 | 18 | 2.7 | 4 | sotorasib 960 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:57.639708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185444 | REC_0003224 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 16.3 | 65 | male | 0 | 18 | 7.3 | 2 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:57.639949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543898 | REC_0003225 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 8.8 | 59 | female | 1 | 18 | 5.8 | 6 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:35:57.640331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468332 | REC_0003226 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.9 | 70 | male | 2 | 40 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.8 | true | MSS | 2026-03-15T05:35:57.640604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180694 | REC_0003227 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 2 | 63 | male | 1 | 45 | 7.7 | 5 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:57.640860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692250 | REC_0003228 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18.1 | 53 | female | 0 | 13 | 3.3 | 5 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.641104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692617 | REC_0003229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.6 | 54 | male | 0 | 21 | 2.6 | 8 | entrectinib 600 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:57.641353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909320 | REC_0003230 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.1 | 60 | female | 0 | 11 | 5 | 6 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:57.641605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102243 | REC_0003231 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.4 | 59 | male | 1 | 25 | 6.4 | 3 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.641845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978915 | REC_0003232 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 9.3 | 59 | male | 0 | 13 | 5.4 | 2 | osimertinib 80 mg daily | 19.7 | false | MSS | 2026-03-15T05:35:57.642092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680275 | REC_0003233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.1 | 82 | female | 2 | 18 | 5.7 | 4 | alectinib 600 mg BID | 13.1 | true | MSI-H | 2026-03-15T05:35:57.642333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298051 | REC_0003234 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.2 | 65 | female | 1 | 64 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.3 | false | MSS | 2026-03-15T05:35:57.642574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921305 | REC_0003235 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4 | 54 | female | 0 | 15 | 3.8 | 2 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:57.642817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235746 | REC_0003236 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.5 | 81 | female | 1 | 27 | 4.6 | 5 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.643056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728745 | REC_0003237 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.3 | 69 | male | 0 | 17 | 8.6 | 7 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:35:57.643306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624140 | REC_0003238 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 12.3 | 71 | female | 2 | 23 | 5.7 | 1 | entrectinib 600 mg daily | 27.6 | false | MSS | 2026-03-15T05:35:57.643702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172313 | REC_0003239 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.4 | 82 | female | 3 | 17 | 6.6 | 7 | osimertinib 80 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:57.643968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385128 | REC_0003240 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.3 | 68 | male | 0 | 4 | 5.3 | 4 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:57.644296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469883 | REC_0003241 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 10.7 | 69 | male | 0 | 25 | 5.7 | 2 | pembrolizumab 200 mg q3w | 23.9 | false | MSS | 2026-03-15T05:35:57.644566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774768 | REC_0003242 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 11.8 | 65 | male | 0 | 11 | 7.9 | 6 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:35:57.644820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258930 | REC_0003243 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5 | 58 | female | 1 | 0 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:57.645062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100870 | REC_0003244 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.2 | 62 | female | 0 | 8 | 4.5 | 1 | alectinib 600 mg BID | 19 | true | MSS | 2026-03-15T05:35:57.645308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646056 | REC_0003245 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.5 | 64 | male | 1 | 17 | 5.7 | 2 | sotorasib 960 mg daily | 23.1 | true | MSS | 2026-03-15T05:35:57.645558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819847 | REC_0003246 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.8 | 72 | female | 2 | 14 | 6.4 | 7 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:57.645820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776781 | REC_0003247 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.5 | 68 | male | 1 | 19 | 7.4 | 5 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.646084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473522 | REC_0003248 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 8.4 | 63 | male | 1 | 11 | 3.8 | 1 | sotorasib 960 mg daily | 5.3 | true | MSS | 2026-03-15T05:35:57.646348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144642 | REC_0003249 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 11.5 | 81 | female | 2 | 19 | 2.7 | 4 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.646605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955921 | REC_0003250 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.4 | 70 | female | 2 | 42 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 9 | false | MSS | 2026-03-15T05:35:57.646856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196651 | REC_0003251 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.8 | 75 | male | 2 | 21 | 5.6 | 6 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:57.647241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419513 | REC_0003252 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.8 | 64 | female | 0 | 13 | 3.6 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.647489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224121 | REC_0003253 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 15 | 11.6 | 82 | female | 3 | 10 | 5.7 | 0 | osimertinib 80 mg daily | 33.5 | false | MSI-H | 2026-03-15T05:35:57.647730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690384 | REC_0003254 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.1 | 68 | female | 0 | 65 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.1 | false | MSS | 2026-03-15T05:35:57.647969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519481 | REC_0003255 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14.1 | 79 | female | 1 | 21 | 6.9 | 2 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:57.648286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181692 | REC_0003256 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 15.3 | 67 | male | 1 | 21 | 4.1 | 2 | osimertinib 80 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:35:57.648534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569672 | REC_0003257 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.9 | 78 | female | 1 | 16 | 4.8 | 7 | entrectinib 600 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:57.648783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355078 | REC_0003258 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.9 | 64 | male | 1 | 12 | 5.8 | 2 | sotorasib 960 mg daily | 17.3 | false | MSI-H | 2026-03-15T05:35:57.649032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168849 | REC_0003259 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 20.4 | 60 | male | 0 | 9 | 6.3 | 6 | entrectinib 600 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:57.649272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353504 | REC_0003260 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.2 | 56 | male | 1 | 15 | 5.7 | 2 | pembrolizumab 200 mg q3w | 30.5 | true | MSS | 2026-03-15T05:35:57.649507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212621 | REC_0003261 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.4 | 70 | female | 2 | 35 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.8 | true | MSS | 2026-03-15T05:35:57.649741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839793 | REC_0003262 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.3 | 65 | female | 0 | 17 | 3.4 | 7 | sotorasib 960 mg daily | 9 | true | MSI-H | 2026-03-15T05:35:57.649977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982820 | REC_0003263 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.5 | 70 | female | 2 | 25 | 5.5 | 7 | sotorasib 960 mg daily | 4.8 | false | MSI-H | 2026-03-15T05:35:57.650210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876067 | REC_0003264 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5 | 72 | female | 1 | 23 | 5 | 5 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:57.650524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841415 | REC_0003265 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 19.7 | 73 | female | 1 | 17 | 3.8 | 8 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:57.650771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332296 | REC_0003266 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.9 | 82 | female | 1 | 14 | 5.6 | 1 | alectinib 600 mg BID | 15.1 | false | MSI-H | 2026-03-15T05:35:57.651003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385570 | REC_0003267 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 6.5 | 61 | female | 0 | 31 | 6.8 | 6 | pembrolizumab 200 mg q3w | 14.6 | false | MSS | 2026-03-15T05:35:57.651239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876787 | REC_0003268 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 10.7 | 55 | female | 1 | 20 | 5 | 3 | osimertinib 80 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:57.651474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722022 | REC_0003269 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 31 | 8.3 | 71 | female | 3 | 20 | 5.7 | 0 | pembrolizumab 200 mg q3w | 52.5 | true | MSS | 2026-03-15T05:35:57.651705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169146 | REC_0003270 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 16.2 | 62 | male | 1 | 18 | 5.2 | 1 | osimertinib 80 mg daily | 21.1 | true | MSS | 2026-03-15T05:35:57.651940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974728 | REC_0003271 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 9.4 | 69 | female | 1 | 4 | 5 | 2 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:35:57.652233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269595 | REC_0003272 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.5 | 71 | male | 3 | 43 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:35:57.652481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493464 | REC_0003273 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.4 | 60 | female | 0 | 16 | 6.1 | 2 | osimertinib 80 mg daily | 20.3 | false | MSI-H | 2026-03-15T05:35:57.652745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653396 | REC_0003274 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.9 | 68 | female | 1 | 13 | 4.6 | 7 | entrectinib 600 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:57.652986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313523 | REC_0003275 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.2 | 72 | female | 2 | 27 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.8 | true | MSS | 2026-03-15T05:35:57.653224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525111 | REC_0003276 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9.8 | 68 | female | 1 | 20 | 5.3 | 8 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:57.653461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975252 | REC_0003277 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 7.1 | 67 | female | 1 | 35 | 5.3 | 1 | pembrolizumab 200 mg q3w | 15.6 | true | MSS | 2026-03-15T05:35:57.653792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323759 | REC_0003278 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 8.8 | 73 | female | 1 | 16 | 6.8 | 3 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.654034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163165 | REC_0003279 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.1 | 79 | female | 1 | 29 | 8.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.2 | true | MSS | 2026-03-15T05:35:57.654263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478575 | REC_0003280 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.9 | 69 | female | 0 | 14 | 7.1 | 4 | osimertinib 80 mg daily | 15.8 | false | MSI-H | 2026-03-15T05:35:57.654501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222545 | REC_0003281 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.1 | 64 | male | 1 | 60 | 3.8 | 1 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:35:57.654737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609233 | REC_0003282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 20.3 | 64 | female | 0 | 25 | 3.9 | 6 | entrectinib 600 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:57.654976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489133 | REC_0003283 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 6.3 | 71 | female | 1 | 24 | 4.6 | 5 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:57.655205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687954 | REC_0003284 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.5 | 64 | male | 0 | 48 | 6.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:35:57.655440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152119 | REC_0003285 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.5 | 61 | female | 0 | 59 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:35:57.655679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766012 | REC_0003286 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 19.6 | 61 | female | 0 | 23 | 6.9 | 1 | sotorasib 960 mg daily | 17 | false | MSS | 2026-03-15T05:35:57.655921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818411 | REC_0003287 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 9.4 | 74 | female | 1 | 16 | 3.5 | 6 | alectinib 600 mg BID | 4.8 | false | MSS | 2026-03-15T05:35:57.656365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208445 | REC_0003288 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 15.5 | 76 | female | 1 | 19 | 4.4 | 1 | sotorasib 960 mg daily | 22.2 | true | MSI-H | 2026-03-15T05:35:57.656688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344928 | REC_0003289 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.7 | 67 | female | 0 | 14 | 5 | 3 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:57.656963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428481 | REC_0003290 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 18.5 | 70 | female | 2 | 11 | 5.5 | 2 | sotorasib 960 mg daily | 26 | false | MSI-H | 2026-03-15T05:35:57.657301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736648 | REC_0003291 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 2.9 | 66 | female | 1 | 31 | 5.9 | 2 | pembrolizumab 200 mg q3w | 12.3 | false | MSS | 2026-03-15T05:35:57.657545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735544 | REC_0003292 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 7.7 | 66 | female | 0 | 17 | 5.9 | 8 | sotorasib 960 mg daily | 7.7 | true | MSS | 2026-03-15T05:35:57.657781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726767 | REC_0003293 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.5 | 80 | female | 1 | 51 | 3.3 | 7 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:57.658017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373947 | REC_0003294 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.4 | 59 | male | 0 | 49 | 6.1 | 2 | pembrolizumab 200 mg q3w | 19.6 | false | MSS | 2026-03-15T05:35:57.658272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349989 | REC_0003295 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 8.8 | 68 | female | 1 | 21 | 4.8 | 2 | osimertinib 80 mg daily | 21.5 | false | MSS | 2026-03-15T05:35:57.658519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852515 | REC_0003296 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 17.5 | 78 | female | 1 | 26 | 5.8 | 8 | osimertinib 80 mg daily | 18 | true | MSI-H | 2026-03-15T05:35:57.658789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720310 | REC_0003297 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 10.4 | 69 | female | 0 | 11 | 4.4 | 7 | pembrolizumab 200 mg q3w | 7.4 | false | MSI-H | 2026-03-15T05:35:57.659068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869682 | REC_0003298 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11.6 | 58 | female | 1 | 25 | 5.6 | 5 | alectinib 600 mg BID | 11.2 | false | MSI-H | 2026-03-15T05:35:57.659347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561123 | REC_0003299 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.5 | 61 | male | 0 | 19 | 6.1 | 5 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:57.659621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396191 | REC_0003300 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 7.1 | 57 | male | 0 | 22 | 4.4 | 6 | alectinib 600 mg BID | 17.1 | true | MSS | 2026-03-15T05:35:57.659877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.